Literature DB >> 21506644

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.

Govind Ragupathi1, Jeffrey R Gardner, Philip O Livingston, David Y Gin.   

Abstract

One of the most widely used and potent immunological adjuvants is a mixture of soluble triterpene glycosides purified from the soap bark tree (Quillaja saponaria). Despite challenges in production, quality control, stability and toxicity, the QS-21 fraction from this extract has exhibited exceptional adjuvant properties for a range of antigens. It possesses an ability to augment clinically significant antibody and T-cell responses to vaccine antigens against a variety of infectious diseases, degenerative disorders and cancers. The recent synthesis of active molecules of QS-21 has provided a robust method to produce this leading vaccine adjuvant in high purity as well as to produce novel synthetic QS-21 congeners designed to induce increased immune responsiveness and decreased toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506644      PMCID: PMC3658151          DOI: 10.1586/erv.11.18

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  42 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

2.  Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Authors:  Kai Deng; Michelle M Adams; Payal Damani; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

3.  Relationship between adjuvant activity and amphipathic structure of soyasaponins.

Authors:  Kenji Oda; Hisashi Matsuda; Toshiyuki Murakami; Shigeji Katayama; Toshiaki Ohgitani; Masayuki Yoshikawa
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

4.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

Authors:  B Morein; B Sundquist; S Höglund; K Dalsgaard; A Osterhaus
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

5.  Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.

Authors:  Lee M Krug; Govind Ragupathi; Chandra Hood; Mark G Kris; Vincent A Miller; Jennifer R Allen; Stacy J Keding; Samuel J Danishefsky; Jorge Gomez; Leslie Tyson; Barbara Pizzo; Valerie Baez; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

6.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

7.  Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

Authors:  Lee M Krug; Govind Ragupathi; Kenneth K Ng; Chandra Hood; Harold J Jennings; Zhongwu Guo; Mark G Kris; Vincent Miller; Barbara Pizzo; Leslie Tyson; Valerie Baez; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Authors:  John M Kirkwood; Judith Manola; Joseph Ibrahim; Vernon Sondak; Marc S Ernstoff; Uma Rao
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

9.  Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.

Authors:  Govind Ragupathi; Philip O Livingston; Chandra Hood; John Gathuru; Susan E Krown; Paul B Chapman; Jedd D Wolchok; Linda J Williams; Roberta C Oldfield; Wen-Jen Hwu
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

10.  Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Authors:  Susan F Slovin; Govindaswami Ragupathi; Cristina Musselli; Krystyna Olkiewicz; David Verbel; Scott D Kuduk; Jacob B Schwarz; Dalibor Sames; Samuel Danishefsky; Philip O Livingston; Howard I Scher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

View more
  44 in total

1.  A Functional Group Approach for Prediction of APPI Response of Organic Synthetic Targets.

Authors:  Konstantin O Zhurov; Laure Menin; Thomas Di Franco; Yury O Tsybin
Journal:  J Am Soc Mass Spectrom       Date:  2015-04-21       Impact factor: 3.109

2.  Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement-intramolecular ketene hetero-Diels-Alder reaction.

Authors:  Rashad R Karimov; Derek S Tan; David Y Gin
Journal:  Tetrahedron       Date:  2018-04-19       Impact factor: 2.457

3.  Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Authors:  Pengfei Wang; Đani Škalamera; Xianwei Sui; Ping Zhang; Suzanne M Michalek
Journal:  ACS Infect Dis       Date:  2019-03-28       Impact factor: 5.084

Review 4.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

5.  Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide.

Authors:  Pengfei Wang; Dattatray A Devalankar; Qipu Dai; Ping Zhang; Suzanne M Michalek
Journal:  J Org Chem       Date:  2016-10-13       Impact factor: 4.354

6.  Rapid assembly of the doubly-branched pentasaccharide domain of the immunoadjuvant jujuboside A via convergent B(C6F5)3-catalyzed glycosylation of sterically-hindered precursors.

Authors:  Rashad R Karimov; Derek S Tan; David Y Gin
Journal:  Chem Commun (Camb)       Date:  2017-05-30       Impact factor: 6.222

7.  Effect of saponin on erythrocytes.

Authors:  Rosi Bissinger; Paola Modicano; Kousi Alzoubi; Sabina Honisch; Caterina Faggio; Majed Abed; Florian Lang
Journal:  Int J Hematol       Date:  2014-06-13       Impact factor: 2.490

8.  Synthesis of QS-21-based immunoadjuvants.

Authors:  Pengfei Wang; Qipu Dai; Punith Thogaripally; Ping Zhang; Suzanne M Michalek
Journal:  J Org Chem       Date:  2013-11-05       Impact factor: 4.354

9.  Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Chem Commun (Camb)       Date:  2015-09-21       Impact factor: 6.222

10.  Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Authors:  Alberto Fernández-Tejada; Eric K Chea; Constantine George; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; Derek S Tan; David Y Gin
Journal:  Bioorg Med Chem       Date:  2014-09-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.